Alexander Snyder. “For Profit or For Health? It Is Time to Reckon With the Current Pharmaceutical Landscape Through a Systematic Analysis of Monoclonal Anitbodies”. Pittsburgh Journal of Technology Law &Amp; Policy, vol. 21, no. 2, Aug. 2021, doi:10.5195/tlp.2021.251.